SNY Sanofi ADR

$49.63

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/21/2025

About Sanofi ADR

Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.

Website: https://www.sanofi.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1121404
Address
54 RUE LA BOETIE, PARIS, FR
Valuation
Market Cap
$126.23B
P/E Ratio
20.52
PEG Ratio
0.87
Price to Book
1.42
Performance
EPS
$2.48
Dividend Yield
4.35%
Profit Margin
12.60%
ROE
7.30%
Technicals
50D MA
$54.87
200D MA
$52.90
52W High
$60.12
52W Low
$44.24
Fundamentals
Shares Outstanding
2B
Target Price
$63.97
Beta
0.48

SNY EPS Estimates vs Actual

● Estimated
● Actual

SNY News & Sentiment

Nov 21, 2025 • Benzinga NEUTRAL
Texas AG Sues Sanofi And Bristol-Myers Over Alleged Failures To Warn About Risks Associated With Blood Thinner Drug - Pfizer ( NYSE:PFE ) , Bristol-Myers Squibb ( NYSE:BMY ) , Sanofi ( NASDAQ:SNY )
Texas Attorney General Ken Paxton escalated his campaign against major drugmakers this week, filing a new lawsuit accusing Sanofi SA ( NASDAQ:SNY ) and Bristol-Myers Squibb Co ( NYSE:BMY ) of concealing critical information about the effectiveness of their blood-thinning medication Plavix.
Nov 20, 2025 • Zacks Commentary SOMEWHAT-BULLISH
REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD
Regeneron gains EC approval to expand Libtayo's use in high-risk CSCC. The FDA approves Eylea HD the treatment of patients with macular edema following retinal vein occlusion.
Nov 20, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Beyond GLP-1: Eli Lilly's Expanding Drug Portfolio Lifts Sales
LLY???s newest approvals and pipeline deals add fresh momentum to revenue growth as the company expands beyond its GLP-1 blockbusters.
Nov 19, 2025 • Benzinga NEUTRAL
EYLEA HD® ( aflibercept ) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion ( RVO ) and for Monthly Dosing Across Approved Indications - Regeneron Pharmaceuticals ( NASDAQ:REGN )
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period TARRYTOWN, N.Y., Nov. 19, 2025 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) today announced that the U.S.
Nov 19, 2025 • GlobeNewswire NEUTRAL
EYLEA HD® ( aflibercept ) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion ( RVO ) and for Monthly Dosing Across Approved Indications
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period ...
Nov 19, 2025 • Business Insider NEUTRAL
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past ...
Sentiment Snapshot

Average Sentiment Score:

0.189
50 articles with scored sentiment

Overall Sentiment:

Bullish

SNY Reported Earnings

Jul 31, 2025
Jun 30, 2025 (Post market)
-0.09 Surprise
  • Reported EPS: $0.91
  • Estimate: $1.00
  • Whisper: —
  • Surprise %: -9.0%
Apr 24, 2025
Mar 31, 2025 (Pre market)
0.07 Surprise
  • Reported EPS: $1.02
  • Estimate: $0.95
  • Whisper: —
  • Surprise %: 7.4%
Jan 30, 2025
Dec 31, 2024 (Pre market)
-0.06 Surprise
  • Reported EPS: $0.68
  • Estimate: $0.74
  • Whisper: —
  • Surprise %: -8.1%
Oct 25, 2024
Sep 30, 2024 (Pre market)
0.16 Surprise
  • Reported EPS: $1.54
  • Estimate: $1.38
  • Whisper: —
  • Surprise %: 11.6%
Jul 25, 2024
Jun 30, 2024 (Pre market)
0.07 Surprise
  • Reported EPS: $0.93
  • Estimate: $0.86
  • Whisper: —
  • Surprise %: 8.1%
Apr 25, 2024
Mar 31, 2024 (Post market)
0.03 Surprise
  • Reported EPS: $0.97
  • Estimate: $0.94
  • Whisper: —
  • Surprise %: 3.2%
Feb 01, 2024
Dec 31, 2023 (Pre market)
-0.61 Surprise
  • Reported EPS: $0.89
  • Estimate: $1.50
  • Whisper: —
  • Surprise %: -40.7%
Oct 27, 2023
Sep 30, 2023 (Pre market)
0.5 Surprise
  • Reported EPS: $2.77
  • Estimate: $2.27
  • Whisper: —
  • Surprise %: 22.0%
Jul 28, 2023
Jun 30, 2023 (Pre market)
-0.6 Surprise
  • Reported EPS: $0.95
  • Estimate: $1.55
  • Whisper: —
  • Surprise %: -38.7%

Financials